Manali says that in rituximab-refractory follicular lymphoma she avoids chemotherapy such as bendamustine because a later CD19 CAR T option may be compromised by prior bendamustine. She would rather use Epco-R2 or MosinLen, preserving the CAR T path for patients who need it. She frames this as a key sequencing decision.
Alex says baseline CRP, ferritin and IL-6 help interpret later changes when a patient develops fever, but they are not specific to CRS and should not guide treatment. IL-6 rises after tocilizumab because the receptor is blocked, making subsequent values hard to interpret in practice.
Spencer, at Lynn Cancer Institute, says his committee had to update multiple EMRs, teach ER doctors, ICU staff, residents and hospitalists about CRS, ensure tocilizumab is available after hours, and secure STAT CMP testing. He describes the coordination across stakeholders as very difficult and the main operational barrier to launching bispecifics.
Manali says third-line DLBCL still favors CD19 CAR T when patients are eligible and CAR-naive, because about 40% have a flat five-year curve suggesting cure. Bispecifics show durable complete responses at three years, but follow-up is shorter. She sequences CAR T first, then a CD20 bispecific.
Jennifer cites a retrospective glofitamab analysis where dexamethasone was associated with lower CRS or less need for additional support than other steroids. Its longer half-life and greater potency made dexamethasone the preferred steroid at Dana-Farber, although she notes the evidence is only retrospective for this drug class.
Alex and Jennifer describe a 'pill in pocket' approach: patients keep dexamethasone at home. If they call with fever but stable vital signs, they take one dose, monitor temperature every one to two hours, and call back for recurrent fever. Many avoid admission, though repeat fever triggers evaluation.
Alex says one-and-done vaccines such as RSV, shingles and pneumonia are best given before a bispecific or at least a year after, when immune response is likely better. Flu and COVID vaccines are still recommended, but she spaces them six to eight weeks before PET to avoid vaccine-related adenopathy.
Spencer describes a phased plan where patients receive first bispecific doses at a tertiary center and then transfer back to the community. Jennifer and Alex note CRS is mostly front-loaded, with delayed events rare beyond early doses. This model reduces community safety burden, but the community still must handle later fevers.
Alex admits some patients preemptively even when outpatient dosing is possible: those living alone with limited support, patients with heart failure or chronic kidney disease, and those with high tumor burden, LDH above 1,000, or malignant effusions. The aim is faster recognition and treatment of CRS.
Manali says there is no data for prophylactic tocilizumab with lymphoma CD20 bispecifics, unlike myeloma, so she does not use it. Patients instead receive PJP and HSV prophylaxis and have IgG checked, with IVIG for IgG below 400 or recurrent infections. That prophylaxis package differs from CAR T.
Manali reports Epco-R2's phase 3 follicular lymphoma trial showed a hazard ratio of 0.2 for PFS, but grade 3 or higher infections hit 33% and neutropenia 69%. MosinLen had less infection and is a time-limited doublet. If approved, the choice may trade triplet efficacy for better tolerability.
Manali emphasizes that CD20 expression must be reconfirmed by flow cytometry or IHC before any CD20 bispecific, because the drug cannot work without its target. In her case, a patient retained CD20 after CAR T and then received glofitamab, showing prior CAR T does not rule out bispecific therapy.
Manali explains glofitamab binds the same CD20 epitope as obinutuzumab and had high CRS, so the label requires obinutuzumab seven days before the first step-up. Mosunetuzumab shares rituximab's epitope, meaning a mosunetuzumab-rituximab combination would compete for the same binding domain. That mechanistic detail shapes regimen design.
Jennifer shows CRS timing differs by drug: glofitamab peaks at the first 2.5 mg step-up, epcoritamab at its first full dose, and mosunetuzumab at the third dose. Follicular lymphoma's extra epcoritamab step-up lowered high-grade CRS. Outpatient monitoring must match the exact agent and dose in practice.
Alex has bispecific patients keep flu and COVID tests at home because fever workup must still rule out infection. In one case, a patient had recurrent CRS fevers and later tested positive for flu B, with cough and congestion distinguishing the infection from her earlier fever-only CRS.
Jennifer describes a glofitamab plus Pola-R-CHP trial where two chemotherapy cycles before the bispecific produced almost no CRS, likely from debulking. But patients then received the bispecific at chemotherapy nadir, making febrile neutropenia a real challenge if phase 3 succeeds and the regimen is adopted.
Manali says Epco-R2 caused grade 3 or higher neutropenia in 69% of patients, so co-management with community partners often means dose-reducing or holding lenalidomide to keep epcoritamab going. This practical lever matters as the triplet enters second-line follicular lymphoma practice. It may prevent unnecessary epcoritamab discontinuation.
Tina says her West Virginia site is ninety minutes from academic care, and older follicular lymphoma patients often decline bispecifics because of travel and parking. Spencer sees the same barrier at his Boca Raton site. Repeated bispecific visits are harder than a one-time CAR T trip.
